AbbVie will gain a series of rare disease drugs, including Elaprase for Hunter syndrome, a genetic disorder, and Replagal, to treat Fabry disease. It also inherits experimental products, including lifitegrast for dry eye, and Premiplex for a potentially blinding eye disorder in infants. Premiplex could generate more than $1 billion annually if it reaches the market, said Jason Gerberry, an analyst at Leerink Partners.
Wow! Where have we heard of this one?
Sentiment: Strong Buy
thiis thread for idiots. * INSM is out of the recombinant technology business. They sold all their interests and all the people who knew anything about that business are gonzo. Including the guy they hired
I know you have been here for a long time and should know better to post misleading information like this.
Insmed will receive zero on anything regarding premiplex selling all rights to this last year.all rights.
gertrude_theduck • 22 hours ago Flag
3users liked this postsusers disliked this posts3Reply
5 year old product trial
The iplex production story is a fabrication. No future comments.
insm got what...$11 million for premiplex? and now they're saying it's worth $1 billion annually??? I don't think lewis is that stupid. Something is going on behind the scenes with iPlex - what could it be?
Shire was "gifted" iPlex rights for ROP for the token sum of $11M because they will bear the cost of new manufacturing. Having a commercial supply will make it available for the already FDA-approved indication of short stature in 2018, along with any other potential indications that INSM can trial alone or with partners.